OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-03-31-accounts

OR THE PERIOD 2u April 2022to 31"March 2023 2023
Unrestricted Endowment Totalf Total f
Funds f2023 Funds f 2023 2023 2022
Income From:
Dividends
and interest
30,252 30,252 28,130
Uncashed cheques 742 742
written off
Disposal proceeds on 84,260 84,260 153,917
investment
sales
Total Income 30,994 84p260 115,254 182,047
Expenditure
On:
Charitable
Activities
(198) (198) (1,336)
Support costs (2,600) (8,113) (10,713) (8,379)
Investment
purchases
(55,183) (55,183) (146,872)
Gain/(loss)
on
(89,781) (89,781) 52,872
investment
Movement
on grant
(15,036) (15,036) (33,771)
commitments
Tote Iresources (17,834) (153,077) (170,911) (137,486)
expended
Net 13,160 (68,817) (55,657) 44,561
(outgoing)/incoming
resources
Net movement
in
13,160 (68,817) (55,657) 44,561
funds
Fund balances at 1" 100,208 877,064 977,272 932,711
April 2022
Fund balances at 31u 113,368 808,247 921,615 977,272
March 2023

2023 2022
Notes
Investments
Quoted securities 778,790 868,571
Current assets
Debtors 6,591 6,589
Cash at bank and in 243,897 195,496
hand
Creditors; amounts (107,663) (93,384)
falling due within one
year
Net current assets 921&615 977,272
Income funds
Endowment
funds
808,247 877,064
Unrestricted
funds
113,367 100,208
921,615 ~ 977,272

Unrestricted Endowment Total Total 2022
funds funds 2023
Dividends 28,695 28,695 28,068
Interest 1,557 1,557 62
Uncashed che ues written off 742 742
Disposal proceeds on investment
sales
84,260 84,260 153,917
Totals 30,994 84&260 115,254 182,047
4.
Charitable
activities
Unrestricted Endowment Total Total 2022
funds funds 2023
GGtG fah
Project SF118 198 198 807
Project SF127 529
Totals 198 198 1,336

Unrestricted Endowment Total Total 2022
funds funds 2023
Trustee indemnity insurance 448 448 463
Investment management fees 8,113 8,113 6,116
Accountanc fees 1,800 1,800 1,800
Other support costs 352 352
Totals 2,600 8,113 10,713 8,379

6.
Investments
Quoted securities
investment
portfolio b/f
868,571
Investment
gains/(losses)
(89,781
Investment
portfolio c/f
778,790
Total Investment
2023
778,790
Total Investment
2022
868,571

2023 E 20226
Accrued interest 322 100
Accrued Income 6,269 6,489
Totals 6,591 6,589

2023 E 2022 6
Accruals 1,800 1,800
Other creditors 448 1,205
Grant commitments (note 9 105,415 90,379
Totals 107,663 93,384

Balance Grants Grants paid Grants Balance at
at 1Apr made cancelled 31Mar
2022 2023
SF118 5,115 (198 4,917
SF123 9,644 (9,644)
SF124 2,114 (2,114)
SF125 9,303 9,303
SF127 9,471 9,471
SF128 14,932 (14,932)
SF129 9,865 9,865
SF130 14,935 14,935
SF131 15,000 15,000
SF133 12,624 12,624
SF134 14,600 14,600
SF135 14,700 14,700
Total 90,379 41,924 (2,312) (24,576) 105,415
SF118- The clinicalutility ofexome sequencing approaches and the functional evaluation ofpossible
pathogenic variants - Maggie Williams

Investment ortfolio b/f 868,571
Investment gains/(losses) (89,781)
Investment portfolio c/f 778,790
Investment cash account b/f 8,493
Investment disposals 84,260
Investment purchases (55,183)
Investment management
fees
(8,113)
Investment cash account c/f 29,457
Total Endowment
fund 2023
808,247
Total Endowment
fund 2022
877,064